Want to see CMMB full AI Analyst Report?
CMMB Stock Chart & Stats
$1.67
-$0.02(-0.88%)
At close: 4:00 PM EST
$1.67
-$0.02(-0.88%)
Day’s Range― - ―
52-Week Range$1.35 - $4.92
Previous CloseN/A
Volume58.22K
Average Volume (3M)207.96K
Market Cap
$16.34M
Enterprise Value$3.36M
Total Cash (Recent Filing)$8.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 07, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding7,192,266
10 Day Avg. Volume363,095
30 Day Avg. Volume207,955
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$15.00Price Target Upside798.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage reduces refinancing pressure and interest burden for a pre-revenue biotech. This durable balance-sheet strength increases financial flexibility, extends runway, and improves bargaining power in partner or financing talks, lowering insolvency risk.
Phase 2 Nebokitug Clinical SignalDose-dependent biomarker and fibrosis endpoint improvements provide durable biological proof-of-concept for CCL24 inhibition in PSC and PSC–IBD. Robust mechanistic data strengthens the case for partnerships, regulatory discussions, and a defensible niche in fibro-inflammatory diseases.
Governance And BD Expertise AddedAdding an experienced business-development director and reconfigured audit/nominating committees strengthens oversight and capital-markets credibility. This structural governance upgrade improves strategic partnering capacity and investor confidence over the medium term.
Bears Say
Pre-revenue With Ongoing LossesThe company's structural pre-revenue status and recurring operating losses mean it depends on external financing to progress clinical programs. This persistent funding reliance creates dilution and execution risk, and constrains strategic optionality absent partner deals or successful raises.
Sustained Cash BurnOngoing negative operating and free cash flow means the business cannot self-fund development. Even with improving burn metrics, the structural cash deficit necessitates future financings or partnerships, exposing the pipeline and shareholders to dilution and timing risks.
Eroding Equity And Negative ROEDeclining equity and total assets reflect cumulative losses and capital erosion, weakening balance-sheet resilience. Strongly negative ROE signals persistent value destruction, reducing attractiveness to partners and lenders and limiting ability to fund growth without dilutive financing.
Chemomab Therapeutics News
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $1.35 and its highest was $4.92 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $16.34M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 35 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on May 14, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.003.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,192,266 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.003 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went down -2.299%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
CMMB Stock 12 Month Forecast
Average Price Target
$15.00
▲(798.20% Upside)
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---